The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therapy product based o...
--Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, with $150 million under management, announc...
Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of c...
Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to c...
-Brain diagnostics innovator BrainScope announced a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s ...
Adding Four New Independent Directors Appoints John Greisch as Executive Chair Establishes New Strategic and Operational Review Committee of the Board ...
Series C is led by Koch Disruptive Technologies and includes Bristol Myers Squibb, DFJ Growth, Willett Advisors and existing investors Eclipse, Dech...
Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to...
Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire Pheno...
Revenue of $1.18 billion for Q2 2023, up 1% from Q2 2022 (up 3% on a constant currency basis) and up 8% from Q1 2023 Shipped 109 NovaSeq X instruments i...
Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56M Updates FY 2023 guidance and prov...
Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 17% Year-Over-Year to $3.0 billion Oncology Sales...
Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organ...
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia Proposed acquisition ...
© 2025 Biopharma Boardroom. All Rights Reserved.
